SARC partners with SFA and QuadW in support of clinical trial of anti-PD1 agent

DEC. 22, 2014 – ANN ARBOR, MICH. – Focused on their mission to identify new treatments for sarcoma, an uncommon cancer, SARC has leveraged a generous donation to secure the support of the Sarcoma Foundation of America (SFA) and the What Would Willie Want Foundation (QuadW) in a collaborative effort to support a new multi-institutional clinical trial of an anti-PD1 agent. The company who is providing their drug and support for the study of soft tissue sarcoma agreed to provide their drug to study bone sarcomas if additional funding could be secured. SARC secured generous commitments from the Sarcoma Foundation…  Read More »